MicrobiotiX has successfully completed an extended Series B funding round, securing an additional 5 billion KRW following an initial 15 billion KRW investment last October. This includes a 2.5 billion KRW clinical grant from the Korean Ministry of Health and Welfare.
SEOUL, South Korea, Sept. 03, 2025 – MicrobiotiX, a biotechnology firm focused on innovative bacteriophage-based therapies, has successfully concluded an extended Series B investment round, bringing its total funding to 20 billion KRW, the company announced on the 29th.
This latest funding pushes MicrobiotiX’s cumulative investment across all rounds to 29 billion KRW.
After initially securing 15 billion KRW for its Series B in October 2024, the company finalized the round this month with an additional 5 billion KRW injection from new participants such as Paratus Investment, Pureun Investment, and OTIUM CAPITAL.
MicrobiotiX specializes in bacteriophage therapy, addressing illnesses stemming from “super bacteria” or multidrug-resistant pathogens. Its comprehensive platform for phage therapy development features a specialized phage library panel for multidrug-resistant bacteria, an in silico module, and a cGMP-compliant phage manufacturing facility.
The company recently gained selection for the Korean Ministry of Health and Welfare’s “Infectious Disease Prevention and Treatment Technology Development Project,” which aims to advance clinical-stage assets addressing critical unmet medical needs. This prestigious clinical grant is valued at 2.5 billion KRW. Empowered by this funding, MicrobiotiX is poised to launch Korea’s inaugural human clinical trial for phage therapy.
This vital government funding is expected to significantly hasten the research and development efforts required for the commercialization of its phage therapies and future pipeline growth.
Dongeun Yong, CEO of MicrobiotiX, stated: “With this investment and the government project selection, MicrobiotiX seeks to establish itself and Korea as a global leader in the phage therapy field. Through conducting the first clinical trial of its kind in Korea, we are responding to the global health crisis presented by antibiotic-resistant bacterial infections. Simultaneously, we are looking to further enhance the competitiveness and global status of the Korean bio-industry. MicrobiotiX will continue to grow as a Korean biotech company that leads the development of innovative anti-infective drugs.”
For inquiries, please contact: Email: bd@microbiotix.net
